Stock Taper
SCREENER COMPARE ANY 2 STOCKS
KLRA
KAILERA THERAPEUTICS, INC.
NASDAQ
$16.21
▼ DOWN 12.52% (-2.32)

KEY STATISTICS

Market Cap$2.10 B
52w High$28.23
52w Low$16.19
Dividend Yield—
Frequency—
P/E—
Volume531.88K
Shares Out.129.57M

COMPANY

LEADERSHIP

Ronald C. Renaud Jr.
CHIEF EXECUTIVE
Ronald C. Renaud Jr.

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 17, 2026
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
145

PRICE TARGET

Target High$48.00
Target Low$36.00
Target Median$42.00
Target Consensus$42.00

PRICE

$16.21 ▼ DOWN 12.52% (−$2.32)
$16.50$17.25$18.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM16.21

About Kailera Therapeutics, Inc.

www.kailera.com ↗

Kailera Therapeutics is a clinical-stage biopharmaceutical company developing innovative injectable and oral therapies, including a dual-action gut hormone receptor agonist, to treat obesity and related conditions.

INDUSTRY

Biotechnology

A PRODUCT KAILERA THERAPEUTICS, INC. IS KNOWN FOR

Ribupatide (KAI-9531)
Ribupatide (KAI-9531)

Ribupatide, Kailera Therapeutics' lead Phase 3 once-weekly injectable GLP-1/GIP dual agonist, is being developed to treat obesity.

COMPETITORS

COMPETITOR
AMGN COMPARE
LLY COMPARE
NVO COMPARE
PFE COMPARE
VKTX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
74
LISTED HERE
17
RANKED BY POSITION SIZE
VTI
0.00% · 1.2M
XSU.TO
0.02% · 1.2M
SCHA
0.02% · 194.6K
OZEM
4.42% · 176.2K
SBIO
1.07% · 159.8K
R2US.L
0.03% · 91.9K
XRSU.L
0.03% · 42.2K
FBCG
0.01% · 37.0K
RSSL
0.03% · 22.0K
HRTS
0.41% · 14.0K
BBSC
0.03% · 13.0K
THNR
1.72% · 5.7K
ETLZ.DE
0.04% · 4.6K
OMFS
0.02% · 3.7K
URTY
0.01% · 1.9K
AVUS
0.00% · 952
RESM
0.05% · 175

INSTITUTIONAL OWNERSHIP

SHARES OWNED
73.41%
HOLDERS
82
TOP 12 OF 82 · RANKED BY POSITION SIZE
Bain Capital Investors LLC
26.3M sh · $578.41M
Bain Capital Life Sciences Investors, LLC
22.6M sh · $497.51M
Rtw Investments, LP
10.8M sh · $237.41M
Canada Pension Plan Investment Board
7.3M sh · $160.92M
Atlas Venture Life Science Advisors, LLC
5.2M sh · $113.92M
Fmr LLC
4.0M sh · $87.48M
Blackrock, Inc.
3.9M sh · $86.55M
Price T Rowe Associates Inc /Md/
3.5M sh · $77.86M
Citadel Advisors LLC
3.2M sh · $71.39M
Adage Capital Partners Gp, L.L.C.
3.2M sh · $70.68M
Wellington Management Group Llp
2.9M sh · $64.31M
Siren, L.L.C.
2.2M sh · $48.78M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
OFFICER: SEE REMARKS
Tregoning Kathleen
Purchase · 175.0K shares
2026-07-06
★
Tregoning Kathleen
— · —
2026-06-29
★
DIRECTOR, OFFICER: CEO & PRESIDENT
Renaud Ronald C JR
Purchase · 38.1K shares
2026-06-09
★
DIRECTOR, OFFICER: CEO & PRESIDENT
Renaud Ronald C JR
Sale · 38.1K shares
2026-06-09